High throughput measurement of Ca++ dynamics in human stem cell-derived cardiomyocytes by kinetic image cytometery: A cardiac risk assessment characterization using a large panel of cardioactive and inactive compounds

Toxicological Sciences

Volumn 148, Issue 2, 2015, Pages 503-516

  Lu, Hua Rong ^a   Whittaker, Ross ^b   Price, Jeffrey H ^b   Vega, Raquel ^b   Pfeiffer, Emily R ^b   Cerignoli, Fabio ^b   Towart, Rob ^c   Gallacher, David J ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b VALA SCIENCES INC   (United States)

^c Audacter Consulting   (United Kingdom)

Author keywords

Action potential (AP); Alternatives to animal testing; Calcium transient dynamics; Cardiac arrhythmias; High content screen (HCS); Human ether go go related gene (HERG); Long QT

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; ACETYLSALICYLIC ACID; AZITHROMYCIN; CALCIUM ION; CARBACHOL; CARBENOXOLONE; CITALOPRAM; DEXTROPROPOXYPHENE; DIGOXIN; DILTIAZEM; DIMENHYDRINATE; FLECAINIDE; IBUTILIDE; ISOPRENALINE; LEMAKALIM; MEXILETINE; NICORANDIL; NITRENDIPINE; PHENYLEPHRINE; PINACIDIL; POTASSIUM CHANNEL HERG; PRIMIDONE; PROCAINAMIDE; RANOLAZINE; SOTALOL; SPARFLOXACIN; TERFENADINE; VERAPAMIL; VERATRIDINE; ZATEBRADINE;

ACTION POTENTIAL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CARDIOVASCULAR RISK; CONTROLLED STUDY; CYTOMETRY; FLOW CYTOMETER; HEART MUSCLE CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; KINETIC IMAGE CYTOMETER; KINETIC IMAGE CYTOMETRY; RISK ASSESSMENT; STEM CELL; ANIMAL TESTING ALTERNATIVE; CALCIUM SIGNALING; CARDIAC MUSCLE CELL; CARDIOTOXICITY; CELL LINE; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; HEART DISEASE; HEART RATE; IMAGE CYTOMETRY; INDUCED PLURIPOTENT STEM CELL; KINETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PROCEDURES; REPRODUCIBILITY; TOXICITY TESTING;

ACTION POTENTIALS; ANIMAL TESTING ALTERNATIVES; CALCIUM SIGNALING; CARDIOTOXICITY; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART DISEASES; HEART RATE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMAGE CYTOMETRY; INDUCED PLURIPOTENT STEM CELLS; KINETICS; MYOCYTES, CARDIAC; PHENOTYPE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; TOXICITY TESTS;

EID: 84952902211     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfv201     Document Type: Article

References (46)

1. Bers, D. M. (2002). Cardiac excitation-contraction coupling. Nature 415, 198-205.
2. Blazeski, A., Zhu, R. J., Hunter, D. W., Weinberg, S. H., Zambidis, E. T., and Tung, L. (2012a). Cardiomyocytes derived from human induced pluripotent stem cells as models for normal and diseased cardiac electrophysiology and contractility. Prog. Biophys. Mol. Biol. 110, 166-177.
3. Blazeski, A., Zhu, R. J., Hunter, D. W., Weinberg, S. H., Boheler, K. R., Zambidis, E. T., and Tung, L. (2012b). Electrophysiological and contractile function of cardiomyocytes derived from human embryonic stem cells. Prog. Biophys. Mol. Biol. 110, 178-195.
4. Bowes, J., Browb, A. J., Hmon, J., Jarolimek, W., Sridhar, A., Waldron, G., and Whitebread, S. (2012). Reducing safetyrelated drug attrition: The use of in vitro pharmacological profiling. Nat. Rev. Drug Discov. 11, 909-922.
5. Braam, S. R., Teroolen, L., Casini, S., Matsa, E., Lu, H. R., Teisman, A., Passier, R., Denning, C., Gallacher, D. J., Towart, R., et al. (2013). Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes. Stem Cell Res. 10, 48-56.
6. Braam, S. R., Teroolen, L., van de Stolpe, A., Meyer, T., Passier, R., and Mummery, C. L. (2010). Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. 4, 107-116.
7. Camelliti, P., Al-Saud, S. A., Smolenski, R. T., Al-Ayoubi, S., Bussek, A., Wettwer, E., Banner, N. R., Bowles, C. T., Yacoub, M. H., and Terracciano, C. M. (2011). Adult heart slices are a multicellular system suitable for electrophysiological and pharmacological studies. J. Mol. Cell. Cardiol. 51, 390-398.
8. 2+ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry. J. Pharmacol. Toxicol. Methods 66, 246-256.
9. Davis, R. P., Casini, S., van den Berg, C. W., Hoekstra, M., Remme, C. A., Dambrot, C., Salvatori, D., Oostwaard, D. W., Wilde, A. A., Bezzina, C. R., et al. (2012). Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 125, 3079-3091.
10. Dick, E., Rajamohan, D., Ronksley, J., and Denning, C. (2010). Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochem. Soc. Trans. 38, 1037-1045.
11. Ficker, E., Kuryshev, Y. A., Dennis, A. T., Obejero-Paz, C., Wang, L., Hawryluk, P., Wible, B. A., and Brown, A. M. (2004). Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol. Pharmacol. 66, 33-44.
12. Gee, K. R., Brown, K. A., Chen, W. N., Bishop-Stewart, J., Gray, D., and Johnson, I. (2000). Chemical and physiological characterization of fluo-4 Ca(2+)-indicator dyes. Cell Calcium 27, 97-106.
13. Godin, D. V., Ng, T. W., and Tuchek, J. M. (1976). Studies on the interaction of propranolol with erythrocyte membranes. Biochim. Biophys. Acta 436, 757-773.
14. Guo, L., Abrams, R. M., Babiarz, J. E., Cohen, J. D., Kameoka, S., Sanders, M. J., Chiao, E., and Kolaja, K. L. (2011). Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 123, 281-289.
15. Harris, K., Aylott, M., Cui, Y., Loutti, J. B., McMahon, N. C., and Sridhar, A. (2013). Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol. Sci. 134: 412-426.
16. Holland, D. R., and Steinberg, M. I. (1979). Electrophysiologic properties of propoxyphene and norpropoxyphene in canine conducting tissues in vitro and in vivo. Toxicol. Appl. Pharmacol. 47, 123-133.
17. Honerjäger, P., and Reiter, M. (1975). The relation between the effects of veratridine on action potential and contractions in mammalian ventricular myocardium. Nauyn-Schmiedeberg's Arch. Pharmacol. 298, 1-28.
18. Kitamura, H., Yokoyama, M., Akita, H., Matsushita, K., Kurachi, Y., and Yamada, M. (2000). Tertiapin potently and selectively blocks muscarinic K+ channels in rabbit cardiac myocytes. J. Pharmacol. Exp. Ther. 293, 196-203.
19. Kocic, I., and Korolkiewicz, K. (1998). Digoxin effects in the guinea pig heart: Interaction with Rimalkalim. Pharmacol. Res. 37, 67-73.
20. Koncz, I., Szel, T., Bitay, M., Cerbai, E., Jaeger, K., Fülöp, F., Jost, N., Virág, L., Orvos, P., Tálosi, L., et al. (2011). Electrophysiological effects of Ivabradine in dog and human cardiac preparations: Potential arrhythmia actions. Eur. J. Pharmacol. 668, 419-426.
21. Lagrutta, A., Wang, J., Fermini, B., and Salata, J. J. (2006). Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current. J. Pharmacol. Exp. Ther. 317, 1054-1063.
22. Lee, P., Klos, M., Bollensdorff, C., Hou, L., Ewart, P., Kamp, T. J., Zhang, J., Bizy, A., Guerrero-Serna, G., Kohl, P., et al. (2012). Simultaneous voltage and calcium mapping of genetically purified human induced pluripotent stem cell-derived cardiac myocyte monolayers. Circ. Res. 110, 1556-1563.
23. Lu, H. R., Hermans, A., and Gallacher, D. J. (2012). Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes? Br. J. Pharmacol. 166, 1490-1502.
24. Lu, H. R., Vlaminckx, E., Hermans, A., Rohrbacher, J., Van Ammel, K., Towart, R., Pugsley, M., and Gallacher, D. J. (2008). Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br. J. Pharmacol. 154, 1427-1438.
25. Lu, H. R., Yan, G. X., and Gallacher, D. J. (2013). A new biomarkerindex of cardiac electrophysiological balance (iCEB)-plays an important role in drug-induced cardiac arrhythmias: Beyond QT-prolongation and Torsades de Pointes (TdPs). J. Pharmacol. Toxicol. Methods 68, 250-259.
26. Lu, Y., and Wang, Z. (1999). Terfenadine block of sodium current in canine atrial myocytes. J. Cardiovasc. Pharmacol. 33, 507-513.
27. Ma, J., Guo, L., Fiene, S. J., Anson, B. D., Thomson, J. A., Kampm, T. J., Kolaja, K. L., Swanson, B. J., and January, C. T. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: Electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 301, H2006-H2017.
28. Milberg, P., Reinsch, N., Wasmer, K., Mönnig, G., Stypmann, J., Osada, N., Breithardt, G., Haverkamp, W., and Eckardt, L. (2005). Transmural dispersion of repolarization as a key factor of arrhythmogenicity in a novel intact heart model of LQT3. Cardiovasc. Res. 65, 397-404.
29. Monfredi, O., Maltseva, L., Spurgeon, H. A., Boyett, M. R., Lakatta, E. G., and Maltsev, V. A. (2013). Beat-to-beat variation in periodicity of local calcium releases contributes to intrinsic variations of spontaneous cycle length in isolated single sinoatrial node cells. PLoS One 8, e67247.
30. Paredes, R. M., Etzier, J. C., Watts, L. T., Zheng, W., and Lechleiter, J. D. (2008). Chemical calcium indicators. Methods 46, 143-151.
31. Polak, S., Wisniowska, B., and Brandys, J. (2009). Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties. J. Appl. Toxicol. 29, 183-206.
32. Pugsley, M. K., Towart, R., Authier, S., Gallacher, D. J., and Curtis, M. J. (2011). Innovation in safety pharmacology testing. J. Pharmacol. Toxicol. Methods 64, 1-6.
33. 2+ dynamics in cultured Guinea pig cardiomyocytes as an in vitro model to identify potential cardiotoxicants. Toxicol. In Vitro 24, 960-972.
34. Reppel, M., Igelmund, P., Egert, U., Juchelka, F., Hescheler, J., and Drobinskaya, I. (2007). Effect of cardioactive drugs on action potential generation and propagation in embryonic stem cell-cerived cardiomyocytes. Cell. Physiol. Biochem. 19, 213-224.
35. Sager, P. T., Gintant, G., Turner, J. R., Pettit, S., and Stockbridge, N. (2014). Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium. Am. Heart J. 167, 292-300.
36. Schramm, G., Zhang, L., Derakhchan, K., Ehrlich, J. R., Belardinelli, L., and Nattel, S. (2004). Ranolazine: Ion-channel-blocking actions and in vivo electrophysiological effects. Br. J. Pharmacol.142, 1300-1308.
37. Sharma, P. P., Sarma, J. S., and Singh, B. N. (1999). Effects of sotalol on the circadian rhythmicity of heart rate and QT intervals with a noninvasive index of reverse-use dependency. J. Cardiovasc. Pharmacol. Ther. 4, 15-21.
38. Shindo, T., Yamada, M., Isomoto, S., Horio, Y., and Kurachi, Y. (1998). SUR2 subtype (A and B)-dependent differential activation of the cloned ATP-sensitive K+ channels by pinacidil and nicorandil. Br. J. Pharmacol. 124, 985-991.
39. Sirenko, O., Cromwell, E. F., Crittenden, C., Wignall, J. A., Wright, F. A., and Rusyn, I. (2013). Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity. Toxicol. Appl. Pharmacol. 273, 500-507.
40. Tinker, A., and Harmer, S. C. (2010). K+ channels in the heart: New insights and therapeutic implications. Exp. Rev. Clin. Pharmacol. 3, 305-319.
41. Vaughan Williams, E. M. (1984). Subgroups of class 1 antiarrhythmic drugs. Eur. Heart J. 5, 96-98.
42. Wahlquist, C., Jeong, D., Rojas-Muñoz, A., Kho, C., Lee, A., Mitsuyama, S., van Mil, A., Park, W. J., Sluijter, J. P., Doevendans, P. A., et al. (2014). Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 508, 531-535.
43. Wible, B. A., Hawryluk, P., Ficker, E., Kuryshev, Y. A., Kirsch, G., and Brown, A. M. (2005). HERG-Lite: A novel comprehensive high-throughput screen for drug-induced hERG risk. J. Pharmacol. Toxicol. Methods 52, 136-145.
44. Yamada, M. (2002). The role of muscarinic K+ channels in the negative chronotropic effect of a muscarinic agonist. J. Pharmacol. Exp. Ther. 300, 681-687.
45. Yang, T., Snyders, D., and Roden, D. M. (2001). Drug block of I(kr): Model systems and relevance to human arrhythmias. J. Cardiovasc. Pharmacol. 38, 737-744.
46. Zeng, H., Lozinskaya, I. M., Lin, Z., Willette, R. N., Brooks, D. P., and Xu, X. (2006). Mallotoxin is a novel human ether-a-gogo-related gene (hERG) potassium channel activator. J. Pharmacol. Exp. Ther. 319, 957-962.